Skin Cancer

The FDA has granted an orphan drug designation to alrizomadlin as a potential therapeutic option for patients with stage IIB-IV melanoma.

Christopher Bunick, MD, PhD, provides an update on benzene contamination in sunscreen, including a recent recall from Johnson & Johnson.

St. Jude Children’s Research Hospital researchers have created a registry to better understand pediatric melanoma.

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma.

OncoSec Medical Inc. and Merck have entered into a supply and clinical trial agreement for pembrolizumab (Keytruda) and tavokinogene telseplasmid (Tavo) for the potential treatment of late-stage metastatic melanoma.

DermTech offers a new way to detect skin cancer without patients having to go under the knife.

Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.

New regulations, latest absorption data, and updates on environmental and health impacts are shaping the world of photoprotection.

Christopher Bunick, MD, PhD, associate professor of dermatology, Yale University and Dermatology Times® editorial advisory board member, weighs in on a recent report revealing certain batches of various sunscreen and after-sun care products were contaminated with benzene, a carcinogen.

This episode will highlight some breaking news coming out of the sun protection world with a report by Valisure, which found in a recent test that 78 different sunscreen and after-sun care products were contaminated with benzene, a potential carcinogen.

David Light, founder and CEO of Valisure, the independent lab that discovered the presence of benzene in multiple brands and batches of sunscreen, sits down with Dermatology Times to discuss the reports' findings and the impact this news will have on the sun protection industry.

A recent test found various brands and batches of sunscreen and after-sun care products contained benzene, a potential carcinogen.

Content-aware image restoration (CARE) technology demonstrated improvement in examining cellular details of skin.

A study published in JAMA Dermatology investigated how consumers look at sunscreen active ingredients in response to an FDA proposed rule.

A study at AAD VMX 2021 presented data on possible association between sex, skin cancer medication, and dermatologic adverse events.

The FDA has granted an Orphan Drug designation to the investigational tumor-infiltrating lymphocyte therapy ITIL-168 for the treatment of patients with stage IIB to IV melanoma.

In this video interview, Melissa Stenstrom, MD, discusses how physicians can promote the use of sun protection and regular skin cancer screenings to help prevent skin cancer among their patients.

A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.

Artificial intelligence diagnostics are less accurate on skin of color than light skin, even when trained on equal numbers of images.

In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.

More detailed tumor classifications, patient data advance surveillance strategies for the high-risk patient population.

With the summer months quickly approaching, we’re discussing the importance of skin cancer screenings, as well as encouraging regular sun protection usage among patients. This episode also touches on the role of telemedicine in skin cancer screenings, top product recommendations for sun protection and tips on managing patient expectations if the patient is diagnosed with skin cancer.

Michael A. Davies, MD, PhD, discusses how he currently approaches treatment for patients advanced BRAF-mutant melanoma as well as exciting areas of current research to address ongoing questions in the community.

The FDA has granted an orphan drug designation to the orally bioavailable, highly-specific G protein-coupled estrogen receptor agonist LNS8801 for the treatment of patients with metastatic uveal melanoma.

Treatment pairing dabrafenib and trametinib could have expanded benefits for patients with melanoma.